Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Successful Treatment of Osteosarcoma Without Methotrexate in a 13-Year-Old Boy With Down Syndrome

Sims, Emma, BS; Nath, Audrey, MD, PhD; Sugalski, Aaron, DO

Journal of Pediatric Hematology/Oncology: January 2019 - Volume 41 - Issue 1 - p 71–73
doi: 10.1097/MPH.0000000000001212
Clinical and Laboratory Observations

Osteosarcoma is the most common primary bone tumor in children, and only 1 article in the literature describes a case of osteosarcoma in a patient with Down syndrome. Although osteosarcoma is generally treated with chemotherapy regimens that include high-dose methotrexate, patients with Down syndrome have heightened sensitivity to the toxicities of methotrexate. The patient from the aforementioned case study died from sepsis soon after treatment with high-dose methotrexate. This case report describes the successful treatment of osteosarcoma in a pediatric patient with Down syndrome without methotrexate.

Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX

The authors declare no conflict of interest.

Reprints: Aaron Sugalski, DO, Department of Pediatrics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, MS 7810, San Antonio, TX 78229 (e-mail: sugalski@uthscsa.edu).

Received July 19, 2017

Accepted April 17, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.